
# Steering Committee Agenda September 11, 2024 | 12:00pm-1:30pm



| Welcome                          | Jim McPherson      |
|----------------------------------|--------------------|
| Executive Update                 | James Washington   |
| ADHS Healthy Horizons Campaign   | Wendy O'Donnell    |
| ADHS Update                      | Marcellina Lopez   |
| Seasonal Illness Update          | Joel Terriquez, MD |
| ADHS Vaccine Equity Update       | Jessie Barbosa, MS |
| County Update                    |                    |
| Pima County      Maricopa County |                    |
| Material Review                  | Karin Szymanski    |
| 10 Things School Nurses Training | Blanca Martinez    |

### **NEXT MEETING DATE:**


Steering Committee Meeting Wednesday, November 13, 2024 12:00pm - 1:30pm



Welcome & Introductions Jim McPherson TAPI tapi

2

4



Staffing update Karin Szymanski, TAPI Contractor • TAPI Website · Educational Material development Social Media Communication (internal and external) • Community Awareness Committee Please feel free to reach out as needed: Karin Szymanski, karins@whyimmunize.org tapi

HRSA Uninsured Program (UIP) Assessment **UIP** Assessment WILLIAMS ASSESSMENT
Claims reimbursements submitted March '20-April '22
50,000 letters sent out to providers
Williams Adely contracted; conducting 31 audits
Ensuring accuracy of claims billed, medically necessary, no pt. balance billing, no duplicated reimbursement
Misused funds, if identified, need to be returned to HRSA Three Phases: ree Phases:

1-Planning; document submission

2-Testing/Fieldwork

Entrance conference 5/16

Virtual walkthroughs, 6/20

3-Reporting; Pre-exit conference, rebuttal if needed

Pre-Exit conference, 8/29


TAPI response due 9/13 tapi



5











9 10





11 12





Jynneos Vaccine Updates

VFC ordering opened in August
Approved for adults 18+ at high risk for mpox infection
Will be added to the FY 2025 VFA order set for uninsured and underinsured adults

COVID-19 Vaccines
Pfizer, Moderna, and Novavax COVID-19 vaccines authorized by the FDA
Pfizer and Moderna available to order in ASIIS for VFC
Awaiting CDC approval to open Novavax ordering
Bridge Access Program (BAP) ended August 2024
Additional CDC funding will be allocated to CHDs for purchasing COVID-19 vaccines for uninsured/underinsured adults

15 16

RSV Vaccines

Pfizer Abrysvo and Nirsevimab/Beyfortus open for VFC ordering in ASIIS

CDC Recommendations:

Maternal RSV vaccine for pregnant people between 32-36 weeks (Abrysvo ONLY)

RSV immunization for infants under 8 months and highrisk older infants (Nirsevimab ONLY)

RSV vaccine for adults 60-74 at increased risk, and every

RSV vaccine for adults 60-74 at increased risk, and every

RSV vaccine for adults 60-74 at increased risk and every

RSV vaccine for adults 60-74 at increased risk.

2024-2025
Seasonal Influenza Vaccines

• VFC ordering open in ASIIS


• Pediatric influenza vaccine presentation guide

• All presentations are trivalent

17 18







### Influenza vaccine



- Recommendation continues: "Routine vaccination for all persons >6 months of age without contraindications"
- Age-appropriate vaccine recommended for all groups EXCEPT:
  - Solid organ transplant recipients on immunosuppressive medications (recommendation is to provide High-dose IIV or adjuvanted IIV)

### COVID-19 vaccine

- COVID-19 hospitalizations increased in children <4- higher with < 6 months of age
  - 50% no undelying condition
- · 2023-2024 provided increased protection against symptomatic infection
- Effectiveness similar among all age groups
- · Local and systemic reactions after vaccine are

  - Increased risk of GBS/ischemic stroke
     Increased risk of GBS after Pfizer vaccination might not be a real risk (4.1/million doses





### Pneumococcal vaccine




22

- Discussion about PCV21 (Capvaxive)- lowering the recommended age to 50 years of age
- PCV21 serotypes cause >80% of invasive pneumococcal vaccine
- There was no consensus about lowering the age from 65 to 50 y.o.
- Recommendation for "Single-dose PCV21 as an option for persons older than 65 y.o. and for those ages 19-64 y.o with high-risk conditions as an OPTION to PCV20 OR PCV15+PPSV23."








### Combination Haemophilus influenzae vaccine

- Vaxelis (DTaP/IPV/Hib/Hep B)- 2,4,6 months
- Included as an alternative to PedVaxHib for Native American or Alaskan native infants
- Infants have detectable concentrations of anti-Hib and long tern protection:
  - Day 30- after 1 dose (75.7% for Vaxelis vs 71.2% for PedVaxHib)
  - Day 150- after 1 dose (83.6% for Vaxelis vs 71.7% for PedVaxHib)

28



27




### Meningococcal vaccine

- Pentavalent vaccine (MenABCWY)- 2 doses (6 months apart) at ages 10-25
- Proven safe in adolescents and young adults
- Immune response decreasing after 24 months for B and A
- MenB vaccine indication will have some "inclusive language"previous indications PLUS:
  - "Any adolescent who desires protection may receive MenB vaccine, even if they are unsure of their future plans which may inform congregate living risk"

29 30

### **HPV** vaccine

- Discussion regarding moving towards fewer doses
  - WHO Expert advisory group has recommended a single dose for ages 9-20
- Recommendations for people ages 27-45 requires shared clinical decision making.



### Dengue vaccine

32

- Dengvaxia will be discontinued due to low
- demand.
   This decision is not due to any concerns regarding
- This decision's not due to any concerns regarding quality, safety or efficacy.
   Dengvaxia will continue to be distributed through public and private markets globally
   The last doses of Dengvaxia will expire at the end of August 2026.
   Given the 3-dose, 1-year series needed for full immunication, individuals should start the
- immunization, individuals should start the Dengvaxia® immunization series no later than August 31, 2025.



31

### Chikungunya vaccine



- Epidemiology mosquito-borne disease outbreaks have occurred in U.S.territories (primarily in Puerto Rico and USVI) and states (FL, TX)
- · Looked at cost-effectiveness of live attenuated vaccines for lab workers and affected populations (adults in U.S. territories)
  - Virus like vaccine (Bavarian Nordic)- >12 y.o
     Live attenuated (IXCHIQ)- >18 y.o



33

### ADHS Vaccine Equity Update

Jessie Barbosa **ADHS** 



35 36


# **Vaccine Equity Updates**

September 11, 2024


Jessie Barbosa, MS Health Equity Program Manager- Vaccine Equity



# We are excited to introduce our new Vaccine Equity Health Educator who will focus on our older adult and rural vaccine outreach prioritization We have reopened the LTCF/SNF Vaccine Education and Technical Assistance Request Portal Patrice can assist with Technical assistance regarding provider enrollment. In person and virtual vaccine education webinars for residents, staff and family. Connection to community-based vaccination resources, including pharmacy partners, and local health departments for vaccines beyond COVID-19. Mobile Clinics and in-home vaccinations Don't hesitate to email him at patrice.nipape@azdhs.gov



37





THANK YOU!

Jessie Barbosa, MS

Health Equity Manager, Vaccine Equity
jessica.barbosa@azdhs.gov
healthequity@azdhs.gov
480-828-0611

39 40






41 42

# Vaccine Equity Program Update

- Five recipients selected for comorbidity community project.
- Working on setting up Long COVID support groups.
- Current focus on education and outreach until new inventory arrives.





43 44





45






47 48




































10 THINGS SCHOOL NURSES
AND HEALTH OFFICE STAFF
NEED TO KNOW ABOUT
WHY WE IMMUNIZE

THURSDAY SEPTEMBER 19, 2024 12:00 - 1:30 PM

1.5 CEU'S

This training focuses on info to help make school nurses' jobs easier.

## **LEARN:**

- ✓ Why vaccines work
- ✓ AZ School requirements
- ✓ Tips for completing the Immunization Data Report





